AAAAAA
Results:
1-22
|
Results: 22
Authors:
Fisher, RI
Citation: Ri. Fisher, Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: Lessons learned and challenges remaining, J NAT CANC, 93(1), 2001, pp. 4-5
Authors:
Hahn, T
Wolff, SN
Czuczman, M
Fisher, RI
Lazarus, HM
Vose, J
Warren, L
Watt, R
McCarthy, PL
Citation: T. Hahn et al., The role of cytotoxic therapy with hematopoietic stem cell transplantationin the therapy of diffuse large cell B-Cell non-Hodgkin's lymphoma: An evidence-based review, BIOL BLOOD, 7(6), 2001, pp. 308-331
Authors:
Fisher, RI
Citation: Ri. Fisher, Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting, CLIN CANC R, 7(7), 2001, pp. 1835-1836
Authors:
Gaynor, ER
Unger, JM
Miller, TP
Grogan, TM
White, LA
Mills, GM
Balcerzak, SP
Varterasian, M
LeBlanc, M
Fisher, RI
Citation: Er. Gaynor et al., Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study, J CL ONCOL, 19(3), 2001, pp. 750-755
Authors:
Press, OW
LeBlanc, M
Lichter, AS
Grogan, TM
Unger, JM
Wasserman, TH
Gaynor, ER
Peterson, BA
Miller, TP
Fisher, RI
Citation: Ow. Press et al., Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease, J CL ONCOL, 19(22), 2001, pp. 4238-4244
Authors:
Vose, JM
Link, BK
Grossbard, ML
Czuczman, M
Grillo-Lopez, A
Gilman, P
Lowe, A
Kunkel, LA
Fisher, RI
Citation: Jm. Vose et al., Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma, J CL ONCOL, 19(2), 2001, pp. 389-397
Authors:
Flaherty, LE
Atkins, M
Sosman, J
Weiss, G
Clark, JI
Margolin, K
Dutcher, J
Gordon, MS
Lotze, M
Mier, J
Sorokin, P
Fisher, RI
Appel, C
Du, W
Citation: Le. Flaherty et al., Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II cytokineworking group trials, J CL ONCOL, 19(13), 2001, pp. 3194-3202
Authors:
Braziel, RM
Arber, DA
Slovak, ML
Gulley, ML
Spier, C
Kjeldsberg, C
Unger, J
Miller, TP
Tubbs, R
Leith, C
Fisher, RI
Grogan, TM
Citation: Rm. Braziel et al., The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features, BLOOD, 97(12), 2001, pp. 3713-3720
Authors:
Fisher, RI
Rosenberg, SA
Fyfe, G
Citation: Ri. Fisher et al., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma, CA J SCI AM, 6, 2000, pp. S55-S57
Authors:
Taylor, CW
LeBlanc, M
Fisher, RI
Moore, DF
Roach, RW
Elias, L
Miller, TP
Citation: Cw. Taylor et al., Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group Trial, ANTI-CANC D, 11(9), 2000, pp. 695-700
Authors:
Fisher, RI
Citation: Ri. Fisher, Diffuse large-cell lymphoma, ANN ONCOL, 11, 2000, pp. 29-33
Authors:
Fisher, RI
LeBlanc, M
Miller, T
Citation: Ri. Fisher et al., Interferon does not prolong progression-free survival after ProMACE-MOPP -In reply, J CL ONCOL, 18(18), 2000, pp. 3322-3322
Authors:
Fisher, RI
Dana, BW
LeBlanc, M
Kjeldsberg, C
Forman, JD
Unger, JM
Balcerzak, SP
Gaynor, ER
Roy, V
Miller, T
Citation: Ri. Fisher et al., Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809, J CL ONCOL, 18(10), 2000, pp. 2010-2016
Authors:
Fisher, RI
Citation: Ri. Fisher, Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma, SEMIN ONCOL, 27(6), 2000, pp. 2-8
Authors:
Gale, RP
Park, RE
Dubois, R
Bierman, PJ
Fisher, RI
Loh, KK
Peterson, BA
Phillips, GL
Portlock, CS
Rosenblum, D
Armitage, JO
Citation: Rp. Gale et al., Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma (vol 32, pg 139, 1998), LEUK LYMPH, 34(5-6), 1999, pp. NIL_3-NIL_3
Authors:
Atkins, MB
Lotze, MT
Dutcher, JP
Fisher, RI
Weiss, G
Margolin, K
Abrams, J
Sznol, M
Parkinson, D
Hawkins, M
Paradise, C
Kunkel, L
Rosenberg, SA
Citation: Mb. Atkins et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993, J CL ONCOL, 17(7), 1999, pp. 2105-2116
Authors:
Cheson, BD
Horning, SJ
Coiffier, B
Shipp, MA
Fisher, RI
Connors, JM
Lister, TA
Vose, J
Grillo-Lopez, A
Hagenbeek, A
Cabanillas, F
Klippensten, D
Hiddemann, W
Castellino, R
Harris, NL
Armitage, JO
Carter, W
Hoppe, R
Canellos, GP
Citation: Bd. Cheson et al., Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, J CL ONCOL, 17(4), 1999, pp. 1244-1253
Authors:
Moore, DF
Brown, TD
LeBlanc, M
Dahlberg, S
Miller, TP
McClure, S
Fisher, RI
Citation: Df. Moore et al., Phase II trial of menogaril in non-Hodgkin's lymphomas: A Southwest Oncology Group trial, INV NEW DR, 17(2), 1999, pp. 169-172
Authors:
Rizzo, P
Carbone, M
Fisher, SG
Matker, C
Swinnen, LJ
Powers, A
Di Resta, I
Alkan, S
Pass, HI
Fisher, RI
Citation: P. Rizzo et al., Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma, CHEST, 116(6), 1999, pp. 470S-473S
Authors:
Horning, SJ
Yahalom, J
Tesch, H
Fisher, RI
Raemaekers, JMM
Citation: Sj. Horning et al., Treatment of stage III-IV Hodgkin's disease, HODGKIN'S DISEASE, 1999, pp. 483-506
Authors:
Gale, RP
Park, RE
Dubois, R
Bierman, PJ
Fisher, RI
Loh, KK
Peterson, BA
Phillips, GL
Portlock, CS
Rosenblum, D
Armitage, JO
Citation: Rp. Gale et al., Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma, LEUK LYMPH, 32(1-2), 1998, pp. 139-147
Authors:
Fisher, RI
Citation: Ri. Fisher, Treatment of grey zone lymphomas, ANN ONCOL, 9, 1998, pp. 121-123
Risultati:
1-22
|